Our Ozempic lawyers are currently accepting cases for patients who developed: Primary Qualifying Conditions: Gastroparesis (stomach paralysis or gastric stasis) Bowel obstruction, ileus, or intestinal blockage requiring hospitalization or surgery Vision loss, including NAION (non-arteritic anterior ischemic optic neuropathy) Sudden vision loss or blindness in one or both eyes Additional Serious Complications: Gallbladder disease or gallbladder removal Deep vein thrombosis (blood clots) Severe malnutrition requiring medical intervention Organ damage from prolonged gastroparesis To qualify for Ozempic claims, you need: Medical records documenting your diagnosis and treatment Proof you were prescribed Ozempic or took brand-name semaglutide medications (Ozempic, Wegovy, Mounjaro, Trulicity, or Rybelsus) Documented hospitalization, surgery, or ongoing medical treatment for your condition Evidence you took the medication for diabetes management, chronic weight management, or weight loss We do NOT currently accept cases for: common side effects like nausea, vomiting, or diarrhea without a formal gastroparesis or bowel obstruction diagnosis, thyroid issues already labeled on the medication, or cases involving compounded or generic versions of these drugs
Even a few hours of sunlight exposure can degrade the medication
70.9% achieved 10% or more vs 25.6% with liraglutide Once-weekly injection convenience Semaglutide Once-weekly dosing (Wegovy/Ozempic) dramatically reduces injection burden vs daily liraglutide injections Cardiovascular risk reduction in obesity without diabetes Semaglutide SELECT trial demonstrated 20% MACE reduction specifically in overweight/obese adults without diabetes Adolescent obesity treatment Liraglutide Saxenda is approved for adolescents aged 12+ with obesity
Even small deviations from the dosing instructions can significantly reduce the tablets effectiveness
Overall, treatment with semaglutide was associated with a reduction in the studys composite outcomecardiovascular death, nonfatal myocardial infarction or nonfatal strokeof 20% compared to a placebo, and it was linked to a safe and well-tolerated profile. SELECT trial results were published in the New England Journal of Medicine in November
